Get the Weekly Intelligence Brief — top committee picks every Sunday.

ACAD vs AZN

ACADIA Pharmaceuticals Inc. vs AstraZeneca PLC — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
AZN
AstraZeneca PLC
56
Watch
MetricACADAZN
AI Score 69 56
Price $29.41 $158.74
P/E Ratio 13.07× 23.81×
ROE 31.9% 21.1%
Revenue Growth YoY
Gross Margin 91.1% 79.3%
Debt / Equity 0.06× 0.64×
Dividend Yield 0.0% 1.3%
RSI (14) 78.4 33.8
Beta 0.845 0.211
Expected Upside

AI Committee View

Current Innellis committee reasoning for ACAD versus AZN.
ACAD leads by 13 points.

ACAD scores 69/100 (Buy) versus AZN at 56/100 (Watch).

ACAD Committee View
83% agreement
6 analysts

The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.

Bull Case
  • P/E of 13.2 is inexpensive for the broad market — Value
  • ROE of 32.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
  • RSI at 78 is in overbought territory — Technical
  • Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
  • Bollinger bandwidth of 24.3% signals elevated volatility — Risk
AZN Committee View
50% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — current ratio of 0.94 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • ROE of 21.7% shows genuine earnings power backing the valuation — Value
  • EPS growing 25.9% YoY — Growth
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • Price-to-book of 5.9x prices in significant intangible value — Value
  • Price structure making lower highs and lower lows — Technical
  • MACD histogram negative -- bearish momentum — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ACAD Full Analysis AZN Full Analysis